The mean serum protein-bound iodine (PBI) level in 36 cases of cerebral disease with seizures treated by administration of diphenylhydantoin was 3.81 ±0.14 (s. E.) jug. per 100 ml. This was significantly lower than the corresponding mean PBI level in 12 cases of cerebral seizure not so treated, viz., 5.39 + 0.16 Hg. per 100 ml. Despite the occurrence of PBI levels as low as 2.4 ng. per 100 ml. in the diphenylhydantoin group, there was no clinical evidence of hypothyroidism in any of the patients and there were no significant alterations in the other parameters of thyroid function. In 7 of 8 euthyroid subjects, diphenylhydantoin also depressed the serum PBI concentration. The mechanism of action of diphenylhydantoin is apparently extrathyroidal, since this drug depressed the PBI level in hypothyroid patients maintained with a constant dosage of desiccated thyroid. Diphenylhydantoin added in vitro consistently increased the uptake of I 131 -labeled 3,5,3'-triiodothyronine by red blood cells incubated with plasma. This effect was progressively diminished by the addition of increasing quantities of stable Z-thyroxine to the incubating mixture. These data are compatible with the thesis that diphenylhydantoin depresses the level of serum PBI by interfering with the binding of thyroxine by plasma proteins.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.